CV Science

Oliver Kepp PhD; HDR

Course and current status

Since 2022 DR, INSERM U1138, Centre de Recherche des Cordeliers, Paris, France

Since 2019 Cofounder Samsara Therapeutics, Oxford, UK

Since 2013 Director Cell Biology platform, Gustave Roussy Cancer Center, Villejuif, France

2012-2021 CR, INSERM U1138 (KroemerLab), Centre de Recherche des Cordeliers, Paris, France

2010-2011 INSERM PostDoctoral fellow, Gustave Roussy Cancer Center, Villejuif, France

2008-2010 EMBO fellow, INSERM U848 (KroemerLab), Gustave Roussy Cancer Center, Villejuif, France

2007 Max Planck PostDoctoral fellow, Max Planck Institute for Infection Biology, Berlin, Germany

Until 2006 PhD student, Max Planck Institute for Infection Biology, Humboldt University, Berlin, Germany

Scientific summary

Dr. Oliver Kepp graduated from Humboldt University Berlin and obtained a PhD degree in Molecular Biology for his work on "Host cell apoptosis" conducted at the Max Planck Institute for Infection Biology. Following he was a Max Planck postdoctoral research fellow and in 2007 joined the INSERM team headed by Prof. Guido Kroemer at the Gustave Roussy Cancer Center (GRCC) as an EMBO postdoc fellow. He is now a research director at INSERM and the director of the BioCell automation platform at GRCC. In his work he together with his team investigates several aspects of tumor immunogenicity, focusing on systematic cell biology approaches. Oliver published about 350 scientific articles and has a Hirsch factor of 109 (scholar.google.com). He is a member of several editorial boards, a co-founder of Samsara Therapeutics and has been appointed associate director of the European academy of tumor immunology in 2019. Oliver received the prestigious Highly Cited Researcher Award (Clarivate) six years in a row since 2018 and the Biology and Biochemistry Leader Award (Research.com) in 2022 and 2023. Moreover, he has recently been ranked among the top biology and biochemistry scientists in the world (www.research.com).